LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 29

Search options

  1. Article ; Online: QT prolongation with anticancer drugs: a multimodal issue - Authors' reply.

    Giraud, Eline L / van Erp, Nielka P / Smolders, Elise J

    The Lancet. Oncology

    2022  Volume 23, Issue 12, Page(s) e523

    MeSH term(s) Humans ; Long QT Syndrome/chemically induced ; Long QT Syndrome/diagnosis ; Antineoplastic Agents/adverse effects
    Chemical Substances Antineoplastic Agents
    Language English
    Publishing date 2022-11-30
    Publishing country England
    Document type Letter ; Comment
    ZDB-ID 2049730-1
    ISSN 1474-5488 ; 1470-2045
    ISSN (online) 1474-5488
    ISSN 1470-2045
    DOI 10.1016/S1470-2045(22)00695-7
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5696: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 460: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Meropenem to Treat Valproic Acid Intoxication.

    Smolders, Elise J / Ter Heine, Rob / Natsch, Stephanie / Kramers, Kees

    Therapeutic drug monitoring

    2022  Volume 44, Issue 3, Page(s) 359–362

    Abstract: Abstract: This therapeutic drug monitoring (TDM) grand round describes a patient with serious valproic acid intoxication. A total valproic acid level of 844 mg/L and an unbound valproic acid level of 604 mg/L were observed. Meropenem was administered to ...

    Abstract Abstract: This therapeutic drug monitoring (TDM) grand round describes a patient with serious valproic acid intoxication. A total valproic acid level of 844 mg/L and an unbound valproic acid level of 604 mg/L were observed. Meropenem was administered to enhance the clearance of valproic acid. This off-label usage of meropenem is based on the drug-drug interaction between carbapenems and valproic acid, which reduced the level of valproic acid within 24 hours after administration.
    MeSH term(s) Anti-Bacterial Agents/therapeutic use ; Anticonvulsants/therapeutic use ; Drug Interactions ; Humans ; Meropenem/therapeutic use ; Valproic Acid/therapeutic use
    Chemical Substances Anti-Bacterial Agents ; Anticonvulsants ; Valproic Acid (614OI1Z5WI) ; Meropenem (FV9J3JU8B1)
    Language English
    Publishing date 2022-02-14
    Publishing country United States
    Document type Journal Article
    ZDB-ID 424443-6
    ISSN 1536-3694 ; 0163-4356
    ISSN (online) 1536-3694
    ISSN 0163-4356
    DOI 10.1097/FTD.0000000000000973
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1503: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: What the Product Label Does Not Tell You About Drug-Drug Interaction Management: Time for a Re-Appraisal.

    Burger, David M / le Comte, Marianne / Smolders, Elise J / Jacobs, Tom G / Ter Heine, Rob / Knibbe, Catherijne A J / Pirmohamed, Munir

    Journal of clinical pharmacology

    2023  Volume 63, Issue 11, Page(s) 1181–1185

    Language English
    Publishing date 2023-08-01
    Publishing country England
    Document type Journal Article
    ZDB-ID 188980-1
    ISSN 1552-4604 ; 0091-2700 ; 0021-9754
    ISSN (online) 1552-4604
    ISSN 0091-2700 ; 0021-9754
    DOI 10.1002/jcph.2316
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uf I Zs.176: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Bleeding Complications in a Patient After the Unexpected Interaction between Valproic Acid and Phenprocoumon.

    Wieringa, André / Fiebrich, Helle-Brit / Gelder, Fleur van / Valkenburg, Abraham J / Maring, Jan G / Smolders, Elise J

    Current drug safety

    2023  Volume 19, Issue 1, Page(s) 142–144

    Abstract: Background: Phenprocoumon is a vitamin K antagonist that is widely prescribed in Europe and Latin America for the prophylaxis and treatment of thromboembolic events.: Case presentation: A 90-year-old female was admitted to our hospital with tonic- ... ...

    Abstract Background: Phenprocoumon is a vitamin K antagonist that is widely prescribed in Europe and Latin America for the prophylaxis and treatment of thromboembolic events.
    Case presentation: A 90-year-old female was admitted to our hospital with tonic-clonic seizures, possibly due to dementia syndrome. Valproic acid (VPA) was prescribed for the treatment of seizures. VPA is an inhibitor of cytochrome P450 (CYP) 2C9 enzymes. A pharmacokinetic interaction with phenprocoumon occurred, which is a substrate for CYP2C9 enzymes. The interaction resulted in a strong INR increase and subsequent clinically relevant bleeding in our patient. Valproic acid is not specifically mentioned in the phenprocoumon drug label as a CYP2C9 inhibitor, and in the Dutch medication surveillance database, no medication alert is shown when prescribing this combination, and no interaction with phenprocoumon has been reported so far.
    Conclusion: When prescribing this combination, the prescriber should be warned and advised to intensify INR monitoring if the combination is to be continued.
    MeSH term(s) Female ; Humans ; Aged, 80 and over ; Phenprocoumon/adverse effects ; Phenprocoumon/pharmacokinetics ; Valproic Acid/adverse effects ; Acenocoumarol/pharmacokinetics ; Cytochrome P-450 CYP2C9 ; Aryl Hydrocarbon Hydroxylases ; Anticoagulants/adverse effects
    Chemical Substances Phenprocoumon (Q08SIO485D) ; Valproic Acid (614OI1Z5WI) ; Acenocoumarol (I6WP63U32H) ; Cytochrome P-450 CYP2C9 (EC 1.14.13.-) ; Aryl Hydrocarbon Hydroxylases (EC 1.14.14.1) ; Anticoagulants
    Language English
    Publishing date 2023-03-04
    Publishing country United Arab Emirates
    Document type Case Reports
    ZDB-ID 2250840-5
    ISSN 2212-3911 ; 1574-8863
    ISSN (online) 2212-3911
    ISSN 1574-8863
    DOI 10.2174/1574886318666230310104322
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6400: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: SARS-CoV-2 and HIV protease inhibitors: why lopinavir/ritonavir will not work for COVID-19 infection.

    Smolders, Elise J / Te Brake, Lindsey Hm / Burger, David M

    Antiviral therapy

    2020  Volume 25, Issue 7, Page(s) 345–347

    Abstract: Since the beginning of the outbreak of severe acute respiratory syndrome (SARS) coronavirus (CoV) 2, lopinavir/ritonavir was selected for treatment. The recent publication of Cao et al. in the New England Journal of Medicine showed that lopinavir/ ... ...

    Abstract Since the beginning of the outbreak of severe acute respiratory syndrome (SARS) coronavirus (CoV) 2, lopinavir/ritonavir was selected for treatment. The recent publication of Cao et al. in the New England Journal of Medicine showed that lopinavir/ritonavir treatment did not accelerate clinical improvement compared with standard of care. This raised the question of whether in retrospect we could have known this. The aim of this paper is to gather all the available evidence and to comprehensively discuss this issue.
    MeSH term(s) Antiviral Agents/administration & dosage ; COVID-19/drug therapy ; Drug Therapy, Combination ; Humans ; Lopinavir/administration & dosage ; Ritonavir/administration & dosage ; SARS-CoV-2
    Chemical Substances Antiviral Agents ; Lopinavir (2494G1JF75) ; Ritonavir (O3J8G9O825)
    Keywords covid19
    Language English
    Publishing date 2020-06-26
    Publishing country England
    Document type Journal Article
    ZDB-ID 1339842-8
    ISSN 2040-2058 ; 1359-6535
    ISSN (online) 2040-2058
    ISSN 1359-6535
    DOI 10.3851/IMP3365
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4877: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 174: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Mercaptopurine and Metabolites in Breast Milk.

    Ter Horst, Peter / Smolders, Elise J / den Besten-Bertholee, Daphne

    Breastfeeding medicine : the official journal of the Academy of Breastfeeding Medicine

    2019  Volume 15, Issue 4, Page(s) 277–279

    Abstract: A 35-year-old pregnant woman visited our outpatient clinical questioning the safety of once daily 50 mg mercaptopurine (MP) during pregnancy and lactation, which was successfully treating her Crohn's disease. We measured MP and its metabolites in plasma ... ...

    Abstract A 35-year-old pregnant woman visited our outpatient clinical questioning the safety of once daily 50 mg mercaptopurine (MP) during pregnancy and lactation, which was successfully treating her Crohn's disease. We measured MP and its metabolites in plasma and breast milk and found after 4 hours of intake of MP, no MP or its metabolites in breast milk. We concluded that 4 hours after intake of MP, no exposure of the suckling infant to MP and its metabolites was found while being breastfed.
    MeSH term(s) Adult ; Breast Feeding ; Crohn Disease/drug therapy ; Female ; Humans ; Infant ; Lactation ; Mercaptopurine/administration & dosage ; Mercaptopurine/blood ; Milk, Human/chemistry ; Milk, Human/metabolism ; Pregnancy
    Chemical Substances Mercaptopurine (E7WED276I5)
    Language English
    Publishing date 2019-08-16
    Publishing country United States
    Document type Case Reports ; Journal Article
    ZDB-ID 2234680-6
    ISSN 1556-8342 ; 1556-8253
    ISSN (online) 1556-8342
    ISSN 1556-8253
    DOI 10.1089/bfm.2019.0101
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Review article: clinical pharmacology of current and investigational hepatitis B virus therapies.

    Smolders, Elise J / Burger, David M / Feld, Jordan J / Kiser, Jennifer J

    Alimentary pharmacology & therapeutics

    2019  Volume 51, Issue 2, Page(s) 231–243

    Abstract: Background: Treatment of hepatitis B virus (HBV) infection with current therapy suppresses HBV DNA, but loss of hepatitis B surface antigen (HBsAg; functional cure), is rare. Multiple compounds are under investigation.: Aims: To describe the ... ...

    Abstract Background: Treatment of hepatitis B virus (HBV) infection with current therapy suppresses HBV DNA, but loss of hepatitis B surface antigen (HBsAg; functional cure), is rare. Multiple compounds are under investigation.
    Aims: To describe the pharmacology, including drug interactions, efficacy, safety and mechanisms of action of investigational compounds for HBV infection.
    Methods: Descriptive review using PubMed and Google to identify literature/conference papers on investigational compounds (≥Phase 2) with data on efficacy and safety in HBV-infected patients.
    Results: Bulevirtide, JNJ-56136379, ABI-H0731, REP-2139, and inarigivir decrease HBV DNA/RNA, with greater potency than current nucleos(t)ide analogues. REP-2139 (25%-75% of patients, 20-48 weeks treatment) and inarigivir (26% of patients, 12-24 weeks treatment) induce HBsAg loss. ARO-HBV reduced (>1.5 log
    Conclusions: There are promising investigational therapies for HBV infection. Increasing the potential for HBsAg loss may result in more patients achieving functional cure. However, many knowledge gaps remain such as pharmacokinetics in those with HBV, cirrhosis and renal impairment but also the interaction potential between investigational therapies, risk-benefit profiles, and potential for drug interactions with medications used to treat comorbidities associated with aging.
    MeSH term(s) Antiviral Agents/therapeutic use ; Hepatitis B/epidemiology ; Hepatitis B/therapy ; Hepatitis B virus/drug effects ; Hepatitis B virus/genetics ; Hepatitis B virus/immunology ; Hepatitis B, Chronic/epidemiology ; Hepatitis B, Chronic/therapy ; Humans ; Molecular Targeted Therapy/methods ; Molecular Targeted Therapy/trends ; Nucleic Acids/therapeutic use ; Polymers/therapeutic use ; Therapies, Investigational/methods ; Therapies, Investigational/trends ; Treatment Outcome
    Chemical Substances Antiviral Agents ; Nucleic Acids ; Polymers ; REP 2139
    Language English
    Publishing date 2019-12-16
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 639012-2
    ISSN 1365-2036 ; 0269-2813 ; 0953-0673
    ISSN (online) 1365-2036
    ISSN 0269-2813 ; 0953-0673
    DOI 10.1111/apt.15581
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2206: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: SARS-CoV-2 and HIV protease inhibitors

    Smolders, Elise J / te Brake, Lindsey HM / Burger, David M

    Antiviral Therapy ; ISSN 1359-6535

    why lopinavir/ritonavir will not work for COVID-19 infection

    2020  

    Keywords Pharmacology (medical) ; Pharmacology ; Infectious Diseases ; covid19
    Publisher International Medical Press
    Publishing country uk
    Document type Article ; Online
    DOI 10.3851/imp3365
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  9. Article: SARS-CoV-2 and HIV protease inhibitors: why lopinavir/ritonavir will not work for COVID-19 infection

    Smolders, Elise J / Te Brake, Lindsey Hm / Burger, David M

    Antivir. ther

    Abstract: Since the beginning of the outbreak of severe acute respiratory syndrome (SARS) coronavirus (CoV) 2 lopinavir/ritonavir was selected for treatment. The recent publication of Cao et al in the NEJM[1] showed that lopinavir/ritonavir treatment did not ... ...

    Abstract Since the beginning of the outbreak of severe acute respiratory syndrome (SARS) coronavirus (CoV) 2 lopinavir/ritonavir was selected for treatment. The recent publication of Cao et al in the NEJM[1] showed that lopinavir/ritonavir treatment did not accelerate clinical improvement compared with standard of care. This raised the question if we in retrospect could have known this. The aim of this paper is to gather all the available evidence and to comprehensively discuss this issue.
    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #32589165
    Database COVID19

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  10. Article ; Online: The QT interval prolongation potential of anticancer and supportive drugs: a comprehensive overview.

    Giraud, Eline L / Ferrier, Kaylee R M / Lankheet, Nienke A G / Desar, Ingrid M E / Steeghs, Neeltje / Beukema, Rypko J / van Erp, Nielka P / Smolders, Elise J

    The Lancet. Oncology

    2022  Volume 23, Issue 9, Page(s) e406–e415

    Abstract: Patients with cancer are prone to prolongation of the corrected QT interval (QTc) due to the use of anticancer drugs with QTc-prolonging potential in combination with electrolyte imbalances caused by, for example, gastrointestinal side-effects. However, ... ...

    Abstract Patients with cancer are prone to prolongation of the corrected QT interval (QTc) due to the use of anticancer drugs with QTc-prolonging potential in combination with electrolyte imbalances caused by, for example, gastrointestinal side-effects. However, most anticancer drugs were approved with little information on their QTc-prolonging potential and the added risk of torsade de pointes. The absence of this information on the drug label poses a considerable challenge to clinicians regarding the measures that need to be taken to safely start anticancer treatment. In this Review, we provide a comprehensive overview of the evidence for the QTc-prolonging properties of 205 anticancer drugs and 14 antiemetic drugs available from drug labels, assessment reports, and published studies. We classify the drugs as low-risk, moderate-risk, or high-risk for QTc prolongation. We also discuss the clinical relevance of these findings and include practical recommendations to guide clinicians to select the drugs with the least QTc-prolonging properties and to adequately monitor susceptible patients.
    MeSH term(s) Humans ; Long QT Syndrome/chemically induced ; Long QT Syndrome/complications ; Long QT Syndrome/diagnosis ; Risk Factors ; Torsades de Pointes/chemically induced
    Language English
    Publishing date 2022-08-30
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2049730-1
    ISSN 1474-5488 ; 1470-2045
    ISSN (online) 1474-5488
    ISSN 1470-2045
    DOI 10.1016/S1470-2045(22)00221-2
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5696: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 460: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top